MUC2 Antibody (996/1) - BSA Free

Novus Biologicals | Catalog # NB120-11197

Novus Biologicals
100% Guarantee

Key Product Details

Validated by

Biological Validation

Species Reactivity

Validated:

Human, Mouse

Cited:

Human, Mouse

Applications

Validated:

Immunohistochemistry, Immunohistochemistry-Paraffin, Immunohistochemistry-Frozen, Western Blot, Flow Cytometry, Flow (Intracellular), ICC/IF (Negative)

Cited:

Immunohistochemistry-Frozen, Western Blot, Flow Cytometry, IF/IHC

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG1 Clone # 996/1

Format

BSA Free
View all MUC2 Primary Antibodies »

Product Specifications

Immunogen

This MUC2 Antibody (996/1) was developed against MUC2 tandem repeat peptide

Reactivity Notes

Please note that this antibody is reactive to Mouse and derived from the same host, Mouse. Mouse-On-Mouse blocking reagent may be needed for IHC and ICC experiments to reduce high background signal. You can find these reagents under catalog numbers PK-2200-NB and MP-2400-NB. Please contact Technical Support if you have any questions. Mouse reactivity reported in scientific literature (PMID: 24045942).

Localization

Secreted

Specificity

MUC2 Antibody (996/1) recognizes the human MUC2 mucin, and shows no cross-reactivity with MUC1, MUC3 or MUC4 mucins. In tissue sections colon, liver and prostate stain strongly. It recognizes malignant colonic mucosa and normal mucosa.

Clonality

Monoclonal

Host

Mouse

Isotype

IgG1

Theoretical MW

540 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Scientific Data Images for MUC2 Antibody (996/1) - BSA Free

Immunohistochemistry: MUC2 Antibody (996/1) - BSA Free [NB120-11197]

Immunohistochemistry: MUC2 Antibody (996/1) - BSA Free [NB120-11197]

MUC2-Antibody-996-1-Immunohistochemistry-NB120-11197-img0009.jpg
Immunohistochemistry: MUC2 Antibody (996/1) - BSA Free [NB120-11197]

Immunohistochemistry: MUC2 Antibody (996/1) - BSA Free [NB120-11197]

MUC2-Antibody-996-1-Immunohistochemistry-NB120-11197-img0011.jpg
Flow Cytometry: MUC2 Antibody (996/1) - BSA Free [NB120-11197]

Flow Cytometry: MUC2 Antibody (996/1) - BSA Free [NB120-11197]

Flow Cytometry: MUC2 Antibody (996/1) [NB120-11197] - An intracellular stain was performed on HeLa cells with MUC2 Antibody [996/1] NB120-11197AF647 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647.
Flow Cytometry: MUC2 Antibody (996/1) - BSA Free [NB120-11197]

Flow Cytometry: MUC2 Antibody (996/1) - BSA Free [NB120-11197]

Flow Cytometry: MUC2 Antibody (996/1) [NB120-11197] - Analysis of Allophycocyanin conjugate of NB120-11197. An intracellular stain was performed on HeLa cells with MUC2 (996/1) antibody NB120-11197APC (blue) and a matched isotype control NBP2-27287APC (orange). Cells were fixed with 4% PFA and then permeabli
Flow Cytometry: MUC2 Antibody (996/1) - BSA Free [NB120-11197]

Flow Cytometry: MUC2 Antibody (996/1) - BSA Free [NB120-11197]

Flow Cytometry: MUC2 Antibody (996/1) [NB120-11197] - Analysis of Allophycocyanin conjugate of NB120-11197. An intracellular stain was performed on NTERA-2 cells with MUC2 (996/1) antibody NB120-11197APC (blue) and a matched isotype control NBP2-27287APC (orange). Cells were fixed with 4% PFA and then permea
Flow (Intracellular): MUC2 Antibody (996/1) - BSA Free [NB120-11197]

Flow (Intracellular): MUC2 Antibody (996/1) - BSA Free [NB120-11197]

Flow (Intracellular): MUC2 Antibody (996/1) [NB120-11197] - An intracellular stain was performed on HeLa cells with MUC2 Antibody (996/1) NB120-11197AF488 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 10 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 488.
MUC2 Antibody (996/1) - BSA Free

Immunohistochemistry-Paraffin: Mouse Monoclonal MUC2 Antibody (996/1) [NB120-11197] -

Immunohistochemistry-Paraffin: Mouse Monoclonal MUC2 Antibody (996/1) [NB120-11197] - Staining of mouse colon tissue using MUC2 Antibody. Colon, MUC2 -Green, DAPI-Blue. Antibody dilution - 1:100. Image from a verified customer review.
MUC2 Antibody (996/1) - BSA Free

Western Blot: MUC2 Antibody (996/1) - BSA Free [NB120-11197] -

MDA5-mediated dsRNA sensing is required for intestinal Adar deficiency-induced bowel inflammation and organoid death.a Representative images of Adar (green) and J2 (red) staining in organoids isolated from the ileum of Villin-CreERT2 Adarfl/fl mice and treated with or without 4-OHT (200 nM) for 3 days.Scale bars: 100 μm. b Representative images of J2 staining (green) on ileal sections of Adarfl/fl and Adari delta gut mice (3 dpi). Scale bars: 100 μm. c Survival curves of Adarfl/fl, Adari delta gut, and Adari delta gutMda5−/−mice after tamoxifen induction (n = 5 for Adarfl/fl, n = 8 for Adari delta gut, n = 6 for Adari delta gutMda5−/−). d, hAdarfl/fl, Adari delta gut and Adari delta gutMda5−/− mice after tamoxifen induction at 3-dpi. d Small intestine and colon length (n = 5 for Adarfl/fl, n = 7 for Adari delta gut, n = 6 for Adari delta gutMda5−/−). e H&E staining of intestinal sections. Scale bars: 100 μm. Shown on the right are quantifications of histopathological scores, and lengths of ileal crypts and villi (n = 5). f Representative images of TUNEL staining (green) on the ileal sections. Scale bars: 100 μm. g Immunofluorescence of E-cadherin (red) staining. Scale bars: 100 μm. h Immunofluorescence of Lysozyme (green) and Muc2 (red) staining. Scale bars: 100 μm. i Western blot analysis of ileal samples (n = 3). j Representative images of the growth process of organoids isolated from the ileum of Adari delta gut and Adari delta gutMda5−/− mice treated with or without 4-OHT. Scale bars: 100 μm. Data are presented as the mean +/- SEM. The statistical significance was analyzed using Log-rank (Mantel-Cox) test (Fig. 5c). The remaining statistical differences were determined using one-way ANOVA with multiple comparisons. Source data are provided in the Source data file. Image collected and cropped by CiteAb from the following open publication (https://www.nature.com/articles/s41467-025-63554-4), licensed under a CC-BY license. Not internally tested by Novus Biologicals.
MUC2 Antibody (996/1) - BSA Free

Immunocytochemistry/ Immunofluorescence: MUC2 Antibody (996/1) - BSA Free [NB120-11197] -

MS-induced intestinal epithelium injury was CRHR1 dependent.Photomicrographs of hematoxylin and eosin (H&E) stained (A–E) and immunofluorescence of Mucin 2 (Muc2; mucous-forming protein) (F–J) in proximal colon in all experimental groups. Histological scores (K) were highest in MS, demonstrated injury in MS compared to control. Treatment with Antalarmin and Astressin prevented this MS-induced colonic injury, but not by Astressin-2 beta. Crypt length in μm (L) (red lines in photomicrographs A–E) and the number of Muc2+ goblet cells per crypt (M) were reduced by MS compared to control, and restored to control levels following Antalarmin and Astressin treatment. Astressin-2 beta did not prevent these MS-induced effects. Myeloperoxidase (MPO; μmol/mg protein) expression was increased in MS group and was reduced to a level similar to control by treatment with Antalarmin but not by treatment with Astressin or Astressin-2 beta (N). Western blot analysis of NF-kappa B showed an increase in the phosphorylated expression of NF-kappa B in MS, which was prevented by Antalarmin administration, but not by Astressin or Astressin-2 beta (O,P). Trans-cellular flux of HRP (ng/ml.cm2.min; Q) measured by Ussing Chamber was increased in MS and MS + Astressin-2 beta groups, compared to control, but not in MS + Antalarmin and MS + Astressin groups (P). Results are means, +/-SD. p < 0.05 was considered significant. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/28492284), licensed under a CC-BY license. Not internally tested by Novus Biologicals.
MUC2 Antibody (996/1) - BSA Free

Immunocytochemistry/ Immunofluorescence: MUC2 Antibody (996/1) - BSA Free [NB120-11197] -

MS-induced intestinal epithelium injury was CRHR1 dependent.Photomicrographs of hematoxylin and eosin (H&E) stained (A–E) and immunofluorescence of Mucin 2 (Muc2; mucous-forming protein) (F–J) in proximal colon in all experimental groups. Histological scores (K) were highest in MS, demonstrated injury in MS compared to control. Treatment with Antalarmin and Astressin prevented this MS-induced colonic injury, but not by Astressin-2 beta. Crypt length in μm (L) (red lines in photomicrographs A–E) and the number of Muc2+ goblet cells per crypt (M) were reduced by MS compared to control, and restored to control levels following Antalarmin and Astressin treatment. Astressin-2 beta did not prevent these MS-induced effects. Myeloperoxidase (MPO; μmol/mg protein) expression was increased in MS group and was reduced to a level similar to control by treatment with Antalarmin but not by treatment with Astressin or Astressin-2 beta (N). Western blot analysis of NF-kappa B showed an increase in the phosphorylated expression of NF-kappa B in MS, which was prevented by Antalarmin administration, but not by Astressin or Astressin-2 beta (O,P). Trans-cellular flux of HRP (ng/ml.cm2.min; Q) measured by Ussing Chamber was increased in MS and MS + Astressin-2 beta groups, compared to control, but not in MS + Antalarmin and MS + Astressin groups (P). Results are means, +/-SD. p < 0.05 was considered significant. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/28492284), licensed under a CC-BY license. Not internally tested by Novus Biologicals.
MUC2 Antibody (996/1) - BSA Free

Immunocytochemistry/ Immunofluorescence: MUC2 Antibody (996/1) - BSA Free [NB120-11197] -

MS-induced intestinal epithelium injury was CRHR1 dependent.Photomicrographs of hematoxylin and eosin (H&E) stained (A–E) and immunofluorescence of Mucin 2 (Muc2; mucous-forming protein) (F–J) in proximal colon in all experimental groups. Histological scores (K) were highest in MS, demonstrated injury in MS compared to control. Treatment with Antalarmin and Astressin prevented this MS-induced colonic injury, but not by Astressin-2 beta. Crypt length in μm (L) (red lines in photomicrographs A–E) and the number of Muc2+ goblet cells per crypt (M) were reduced by MS compared to control, and restored to control levels following Antalarmin and Astressin treatment. Astressin-2 beta did not prevent these MS-induced effects. Myeloperoxidase (MPO; μmol/mg protein) expression was increased in MS group and was reduced to a level similar to control by treatment with Antalarmin but not by treatment with Astressin or Astressin-2 beta (N). Western blot analysis of NF-kappa B showed an increase in the phosphorylated expression of NF-kappa B in MS, which was prevented by Antalarmin administration, but not by Astressin or Astressin-2 beta (O,P). Trans-cellular flux of HRP (ng/ml.cm2.min; Q) measured by Ussing Chamber was increased in MS and MS + Astressin-2 beta groups, compared to control, but not in MS + Antalarmin and MS + Astressin groups (P). Results are means, +/-SD. p < 0.05 was considered significant. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/28492284), licensed under a CC-BY license. Not internally tested by Novus Biologicals.
MUC2 Antibody (996/1) - BSA Free

Immunocytochemistry/ Immunofluorescence: MUC2 Antibody (996/1) - BSA Free [NB120-11197] -

MS-induced intestinal epithelium injury was CRHR1 dependent.Photomicrographs of hematoxylin and eosin (H&E) stained (A–E) and immunofluorescence of Mucin 2 (Muc2; mucous-forming protein) (F–J) in proximal colon in all experimental groups. Histological scores (K) were highest in MS, demonstrated injury in MS compared to control. Treatment with Antalarmin and Astressin prevented this MS-induced colonic injury, but not by Astressin-2 beta. Crypt length in μm (L) (red lines in photomicrographs A–E) and the number of Muc2+ goblet cells per crypt (M) were reduced by MS compared to control, and restored to control levels following Antalarmin and Astressin treatment. Astressin-2 beta did not prevent these MS-induced effects. Myeloperoxidase (MPO; μmol/mg protein) expression was increased in MS group and was reduced to a level similar to control by treatment with Antalarmin but not by treatment with Astressin or Astressin-2 beta (N). Western blot analysis of NF-kappa B showed an increase in the phosphorylated expression of NF-kappa B in MS, which was prevented by Antalarmin administration, but not by Astressin or Astressin-2 beta (O,P). Trans-cellular flux of HRP (ng/ml.cm2.min; Q) measured by Ussing Chamber was increased in MS and MS + Astressin-2 beta groups, compared to control, but not in MS + Antalarmin and MS + Astressin groups (P). Results are means, +/-SD. p < 0.05 was considered significant. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/28492284), licensed under a CC-BY license. Not internally tested by Novus Biologicals.
MUC2 Antibody (996/1) - BSA Free

Immunocytochemistry/ Immunofluorescence: MUC2 Antibody (996/1) - BSA Free [NB120-11197] -

MS-induced intestinal epithelium injury was CRHR1 dependent.Photomicrographs of hematoxylin and eosin (H&E) stained (A–E) and immunofluorescence of Mucin 2 (Muc2; mucous-forming protein) (F–J) in proximal colon in all experimental groups. Histological scores (K) were highest in MS, demonstrated injury in MS compared to control. Treatment with Antalarmin and Astressin prevented this MS-induced colonic injury, but not by Astressin-2 beta. Crypt length in μm (L) (red lines in photomicrographs A–E) and the number of Muc2+ goblet cells per crypt (M) were reduced by MS compared to control, and restored to control levels following Antalarmin and Astressin treatment. Astressin-2 beta did not prevent these MS-induced effects. Myeloperoxidase (MPO; μmol/mg protein) expression was increased in MS group and was reduced to a level similar to control by treatment with Antalarmin but not by treatment with Astressin or Astressin-2 beta (N). Western blot analysis of NF-kappa B showed an increase in the phosphorylated expression of NF-kappa B in MS, which was prevented by Antalarmin administration, but not by Astressin or Astressin-2 beta (O,P). Trans-cellular flux of HRP (ng/ml.cm2.min; Q) measured by Ussing Chamber was increased in MS and MS + Astressin-2 beta groups, compared to control, but not in MS + Antalarmin and MS + Astressin groups (P). Results are means, +/-SD. p < 0.05 was considered significant. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/28492284), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Applications for MUC2 Antibody (996/1) - BSA Free

Application
Recommended Usage

Flow Cytometry

1:10-1:1000

Immunohistochemistry

1:10-1:500

Immunohistochemistry-Frozen

1:10-1:500

Immunohistochemistry-Paraffin

1:10-1:500

Western Blot

1:100-1:2000
Application Notes
Membrane permeabilization is required for Flow Cytometry.

Reviewed Applications

Read 2 reviews rated 4 using NB120-11197 in the following applications:

Flow Cytometry Panel Builder

Bio-Techne Knows Flow Cytometry

Save time and reduce costly mistakes by quickly finding compatible reagents using the Panel Builder Tool.

Advanced Features

  • Spectra Viewer - Custom analysis of spectra from multiple fluorochromes
  • Spillover Popups - Visualize the spectra of individual fluorochromes
  • Antigen Density Selector - Match fluorochrome brightness with antigen density
Build Your Panel Now
Flow Cytometry

Formulation, Preparation, and Storage

Purification

Protein A or G purified

Formulation

PBS

Format

BSA Free

Preservative

0.09% Sodium Azide

Concentration

1.0 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

Background: MUC2

MUC2, also called mucin 2, is a member of the mucin protein family which are heavily glycosylated, high molecular weight proteins that are produced by goblet cells in epithelial tissues including the intestinal and respiratory tract (1). Mucins can form gels and function in lubrication of mucosal surfaces which serve as a protective barrier of the epithelial lining and an innate host defense (1). Mucins are divided into two groups based on whether they are membrane-bound or secreted, where MUC2 belongs to the secretory group (1,2). Secreted mucins have a distinctive composition characterized by a large central exon "mucin domain" containing O-glycosylated tandem repeat regions rich in proline, threonine, and serine residues, non-repetitive domains, and cysteine-rich domains (1,2). The mucin domain is flanked by 5' and 3' D domains, a B-like domain, a C-like domain, and a Ck-domain (1,2). MUC2 was the first secretory mucin identified in humans (3,4). Full-length MUC2 protein is synthesized as 5179 amino acids (aa) in length with a theoretical molecular weight of ~540 kDa (5).

Changes or perturbations to MUC2 expression has been associated with a number of disease pathologies (1-4, 6). Specifically, altered MUC2 composition has been indicated in colorectal cancer, inflammatory bowel diseases (IBD) including ulcerative colitis and Chron's disease, and chronic obstructive pulmonary disease (COPD) (1-4, 6). In general, decreased or reduced MUC2 expression is associated with colorectal cancer disease progression and development of IBD (1-4, 6). Additionally, studies have found that upon intestinal infection due to parasites or bacteria MUC2 expression is increased, as is overall mucus secretion (3, 6).

References

1. Pothuraju, R., Krishn, S. R., Gautam, S. K., Pai, P., Ganguly, K., Chaudhary, S., Rachagani, S., Kaur, S., & Batra, S. K. (2020). Mechanistic and Functional Shades of Mucins and Associated Glycans in Colon Cancer. Cancers. https://doi.org/10.3390/cancers12030649

2. Ballester, B., Milara, J., & Cortijo, J. (2019). Mucins as a New Frontier in Pulmonary Fibrosis. Journal of Clinical Medicine. https://doi.org/10.3390/jcm8091447

3. Liu, Y., Yu, X., Zhao, J., Zhang, H., Zhai, Q., & Chen, W. (2020). The role of MUC2 mucin in intestinal homeostasis and the impact of dietary components on MUC2 expression. International Journal of Biological Macromolecules. https://doi.org/10.1016/j.ijbiomac.2020.07.191

4. Allen, A., Hutton, D. A., & Pearson, J. P. (1998). The MUC2 gene product: a human intestinal mucin. The International Journal of Biochemistry & Cell Biology. https://doi.org/10.1016/s1357-2725(98)00028-4

5. Uniprot (Q02817)

6. Kim, Y. S., & Ho, S. B. (2010). Intestinal goblet cells and mucins in health and disease: recent insights and progress. Current Gastroenterology Reports. https://doi.org/10.1007/s11894-010-0131-2

Alternate Names

Intestinal mucin-2, MLP, MUC2, MUC-2, mucin 2, intestinal/tracheal, mucin 2, oligomeric mucus/gel-forming, mucin-2, SMUC

Entrez Gene IDs

4583 (Human)

Gene Symbol

MUC2

UniProt

Q02817 (Human)

Additional MUC2 Products

Product Documents for MUC2 Antibody (996/1) - BSA Free

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot or batch number in the search box below.

Download SDS

Product Specific Notices for MUC2 Antibody (996/1) - BSA Free

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Citations for MUC2 Antibody (996/1) - BSA Free

Customer Reviews for MUC2 Antibody (996/1) - BSA Free (2)

4 out of 5
2 Customer Ratings
5 Stars
50%
4 Stars
0%
3 Stars
50%
2 Stars
0%
1 Stars
0%

Have you used MUC2 Antibody (996/1) - BSA Free?

Submit a review and receive an Amazon gift card!

$25/€18/£15/$25CAN/¥2500 Yen for a review with an image

$10/€7/£6/$10CAN/¥1110 Yen for a review without an image

Submit a review
Amazon Gift Card

Customer Images

Showing  1 - 2 of 2 reviews Showing All
Filter By:
Clear Filters X
  • MUC2 Antibody (996/1) - BSA Free
    Name: Sweta Ghosh
    Application: Immunohistochemistry-Paraffin
    Sample Tested: Colon tissue
    Species: Mouse
    Verified Customer | Posted 05/10/2024
    Colon, MUC2 -Green, DAPI-Blue. Antibody dilution - 1:100
    MUC2 Antibody (996/1) - BSA Free NB120-11197
  • Name: Anonymous
    Application: Immunohistochemistry-Paraffin
    Sample Tested: pig lung
    Species: Other
    Verified Customer | Posted 03/11/2009

There are no reviews that match your criteria.

Showing  1 - 2 of 2 reviews Showing All

Protocols

Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.

FAQs

No product specific FAQs exist for this product.

View all FAQs for Antibodies